



(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)
C07K 16/18 (2006.01)

(21) International Application Number:

PCT/CN2020/126780

(22) International Filing Date:

05 November 2020 (05.11.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2019/115760

05 November 2019 (05.11.2019) CN

(71) Applicant: LANOVA MEDICINES LIMITED COMPANY [CN/CN]; 2889 Jinke Road, Building 10, Room 318, Chamtime Plaza, Shanghai 201203 (CN).

(72) Inventor: LI, Runsheng; 2889 Jinke Road, Building 10, Room 318, Chamtime Plaza, Shanghai 201203 (CN).

(74) Agent: SINO-CREATIVITY INTELLECTUAL PROPERTY LAW FIRM; Room 25A3-1, East Wing, Hanwei Plaza No.7 Guanghua Road, Chaoyang District, Beijing 100020 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODY-DRUG CONJUGATES TARGETING CLAUDIN 18.2

(57) Abstract: Provided are antibody-drug conjugates containing a drug moiety attached to a n antibody or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein. The antibody or the fragment thereof binds to the β 3- β 4 loop (residues 45-63 of SEQ ID NO: 30, NYQGLWRSCVRESSGFTEC) and the β 5 strand (residues 169-172 of SEQ ID NO: 30, YTFG) of CLDN18.2.



PCT

(PCT Rule 92*bis*.1 and
Administrative Instructions, Section 422)

SINO-CREATIVITY INTELLECTUAL PROPERTY
LAW FIRM
Room 25A3-1, East Wing, Hanwei Plaza No. 7
Guanghua Road, Chaoyang District
Beijing 100020
China

Date of mailing (<i>day/month/year</i>) 24 January 2022 (24.01.2022)	
Applicant's or agent's file reference FSP1P203253J	IMPORTANT NOTIFICATION
International application No. PCT/CN2020/126780	International filing date (<i>day/month/year</i>) 05 November 2020 (05.11.2020)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address LANOVA MEDICINES LIMITED COMPANY 2889 Jinke Road, Building 10, Room 318, Chamtime Plaza, Shanghai 201203 China	State of Nationality	State of Residence
	CN	CN
	Telephone No.	
	Facsimile No.	
E-mail address		

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☒ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address LANOVA MEDICINES LIMITED 2889 Jinke Road, Building 10, Room 318, Chamtime Plaza, Shanghai 201203 China	State of Nationality	State of Residence
	CN	CN
	Telephone No.	
	Facsimile No.	
E-mail address		
☐ Notifications by e-mail authorized		

3. Further observations, if necessary:
--

4. A copy of this notification has been sent to:

☒ the receiving Office	☐ the International Preliminary Examining Authority
☐ the International Searching Authority	☒ the designated Offices concerned
☐ the Authority(ies) specified for supplementary search	☐ the elected Offices concerned
	☐ other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Xiao Yunpeng e-mail pct.team2@wipo.int Telephone No. +41 22 338 74 02
--	---